209 related articles for article (PubMed ID: 18094968)
21. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.
Calarota SA; Chiesa A; Zelini P; Comolli G; Minoli L; Baldanti F
Immunology; 2013 Aug; 139(4):533-44. PubMed ID: 23560877
[TBL] [Abstract][Full Text] [Related]
22. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.
Fogg M; Murphy JR; Lorch J; Posner M; Wang F
Virology; 2013 Jul; 441(2):107-13. PubMed ID: 23601786
[TBL] [Abstract][Full Text] [Related]
24. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.
Lin CL; Lo WF; Lee TH; Ren Y; Hwang SL; Cheng YF; Chen CL; Chang YS; Lee SP; Rickinson AB; Tam PK
Cancer Res; 2002 Dec; 62(23):6952-8. PubMed ID: 12460912
[TBL] [Abstract][Full Text] [Related]
25. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
27. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
Long HM; Chagoury OL; Leese AM; Ryan GB; James E; Morton LT; Abbott RJ; Sabbah S; Kwok W; Rickinson AB
J Exp Med; 2013 May; 210(5):933-49. PubMed ID: 23569328
[TBL] [Abstract][Full Text] [Related]
28. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
Wang B; Yao K; Liu G; Xie F; Zhou F; Chen Y
Cell Mol Immunol; 2009 Apr; 6(2):97-103. PubMed ID: 19403058
[TBL] [Abstract][Full Text] [Related]
29. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
30. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.
Paramita DK; Fatmawati C; Juwana H; van Schaijk FG; Fachiroh J; Haryana SM; Middeldorp JM
J Med Virol; 2011 Apr; 83(4):665-78. PubMed ID: 21328382
[TBL] [Abstract][Full Text] [Related]
31. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
[TBL] [Abstract][Full Text] [Related]
32. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.
Hui EP; Taylor GS; Jia H; Ma BB; Chan SL; Ho R; Wong WL; Wilson S; Johnson BF; Edwards C; Stocken DD; Rickinson AB; Steven NM; Chan AT
Cancer Res; 2013 Mar; 73(6):1676-88. PubMed ID: 23348421
[TBL] [Abstract][Full Text] [Related]
34. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
Kuzushima K; Hayashi N; Kudoh A; Akatsuka Y; Tsujimura K; Morishima Y; Tsurumi T
Blood; 2003 Feb; 101(4):1460-8. PubMed ID: 12393434
[TBL] [Abstract][Full Text] [Related]
35. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
Ngo MC; Ando J; Leen AM; Ennamuri S; Lapteva N; Vera JF; Min-Venditti A; Mims MP; Heslop HE; Bollard CM; Gottschalk S; Rooney CM
J Immunother; 2014 May; 37(4):193-203. PubMed ID: 24714353
[TBL] [Abstract][Full Text] [Related]
36. Accumulation of LOX-1
Li X; Li JL; Jiang N; Chen J; Liang ZM; Zhao ZL; Xing YF
Aging (Albany NY); 2020 Dec; 13(1):437-449. PubMed ID: 33290259
[TBL] [Abstract][Full Text] [Related]
37. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
Long HM; Haigh TA; Gudgeon NH; Leen AM; Tsang CW; Brooks J; Landais E; Houssaint E; Lee SP; Rickinson AB; Taylor GS
J Virol; 2005 Apr; 79(8):4896-907. PubMed ID: 15795275
[TBL] [Abstract][Full Text] [Related]
38. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
39. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
40. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.
Tsang CW; Lin X; Gudgeon NH; Taylor GS; Jia H; Hui EP; Chan AT; Lin CK; Rickinson AB
J Virol; 2006 Aug; 80(16):8263-6. PubMed ID: 16873282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
